

Express Mail No.: EL 477 032 354 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Srivastava, Pramod K.

Application No.: To Be Assigned
(Continuation of Application No. 09/489,218)

Group Art Unit: To Be Assigned

Filed: On Even Date Herewith

Examiner: To Be Assigned

For: IMMUNOTHERAPEUTIC STRESS
PROTEIN-PEPTIDE COMPLEXES
AGAINST CANCER

Attorney Docket No.: 8449-183-999



INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the U.S. Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicant respectfully direct the Examiner's attention to the references AA to EM listed on the attached revised form PTO 1449.

The above identified application claims priority under 35 U.S.C. § 120 to U.S. Patent Application Serial No. 09/489,218 filed January 21, 2000; U.S. Patent Application Serial No. 09/061,365 filed April 16, 1998 (now U.S. Patent No. 6,017,544 issued January 25, 2000) and U.S. Patent Application Serial No. 08/315,892 filed September 30, 1994 (now U.S. Patent No. 5,750,119 issued February 12, 1998). Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of prior Application Serial No. 08/315,892 for copies of references AI to AM, AQ to BJ, and BL to EF. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of prior Application Serial No. 09/061,365 for copies of references AN to AP and BK. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of prior Application Serial No. 09/489,218 for copies of references EG to EL. Reference AC, which was made of record in the prosecution history of application Serial No.

08/315,892 while pending as a United States application, is now issued as a United States patent, a copy of which is provided herewith. For reference EM, which is a pending U.S. application, a copy of the application as filed and claims as pending are submitted herewith.

Identification of the above-listed references is not to be construed an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application. Consequently, Applicant respectfully declines to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art". As an alternative, Applicant submits herewith a "revised form PTO 1449" entitled "List of References Cited".

Applicant respectfully requests that the Examiner review the listed references and that the references be made of record in the file history of the application. While not to be construed as indicating that the Examiner should not review and consider fully all the listed references, Attorneys for Applicants particularly direct the Examiner's attention to references AQ, AY, BG, BO, BY, CB, CM, CN, DL, DU, and EE, which were cited by an Examiner in an office action for patent application Serial No. 08/315,892 filed September 30, 1994 (now U.S. Patent No. 5,750,119 issued May 12, 1998), or in a Search Report for a foreign application that is a counterpart to patent application Serial No. 08/315,892 filed September 30, 1994 (now U.S. Patent No. 5,750,119 issued February 12, 1998). The Examiner's attention is also particularly directed to references EG to EM.

Pursuant to 37 C.F.R. § 1.97(b), since it is believed that this information disclosure statement is being filed before the mailing date of the first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A duplicate of this sheet is enclosed.

Date November 14, 2001

Respectfully submitted,

Adriane M. Antler *Reg. No. 31,242*
by Geraldine B. [unclear] *32,605*

Adriane M. Antler

(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosure

Express Mail No.: EL 477 032 354 US

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

8449-183-999

SERIAL NO.

To Be Assigned (Continuation of
Application No. 09/489,218)

APPLICANT

Pramod K. Srivastava

FILING DATE

On Even Date Herewith

GROUP

To Be Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,997,873	12/07/99	Srivastava			
	AB	5,961,979	10/05/99	Srivastava			
	AC	6,168,793	01/02/01	Srivastava et al.			
	AD	5,985,270	11/16/99	Srivastava			
	AE	5,935,576	08/10/99	Srivastava			
	AF	6,048,530	04/11/00	Srivastava			
	AG	6,030,618	02/29/00	Srivastava			
	AH	6,017,544	01/25/00	Srivastava			
	AI	4,690,915	09/01/87	Rosenberg			
	AJ	5,188,964	02/23/93	McGuire et al.			
	AK	5,232,833	08/03/93	Sanders et al.			
	AL	5,288,639	02/22/94	Burnie et al.			
	AM	5,348,945	09/20/94	Berberian et al.			
	AN	5,750,119	05/12/98	Srivastava			
	AO	5,830,464	11/03/98	Srivastava			
	AP	5,837,251	11/17/98	Srivastava			
	EG	09/412,420		Srivastava			10/05/99
	EH	09/454,734		Srivastava			12/06/99
	EI	09/657,722		Srivastava			09/08/00
	EM	09/489,218		Srivastava			09/21/00

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AQ	WO 89/12455	12/28/89	PCT				
	AR	WO 90/02564	03/22/90	PCT				
	AS	WO 91/15572	10/17/91	PCT				
	AT	WO 92/01717	02/06/92	PCT				
	AU	WO 92/08484	05/29/92	PCT				
	AV	WO 92/08488	05/29/92	PCT				
	AW	WO 93/14118	07/22/93	PCT				
	AX	WO 93/17712	09/16/93	PCT				

JC973 US PTO
09/992613
11/14/01

	AY	WO 93/18146	09/16/93	PCT				
	AZ	WO 93/18147	09/16/93	PCT				
	BA	WO 93/18150	09/16/93	PCT				
	BB	WO 93/21529	10/28/93	PCT				
	BC	WO 93/24136	12/09/93	PCT				
	BD	WO 94/03208	02/17/94	PCT				
	BE	WO 94/03599	02/17/94	PCT				
	BF	WO 94/04676	03/03/94	PCT				
	BG	WO 94/11513	05/26/94	PCT				
	BH	GB 2 251 186A	07/01/92	United Kingdom				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	BI	Aldovini et al. (1992) "The New Vaccines", <i>Technology Review</i> pp. 24-31.
	BJ	Barrios et al. (1992) "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines that can circumvent the need for adjuvants and Bacillus Calmette Guérin priming", <i>Eur. J. Immunol.</i> 22:1365-1372.
	BK	Barrios et al. (1994) "Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock proteins of 65 kD", <i>Clin. Exp. Immunol.</i> 98:224-228.
	BL	Barrios et al. (1994) "Heat shock proteins as carrier molecules: <i>in vivo</i> helper effect mediated by <i>Escherichia coli</i> GroEL and DnaK proteins requires cross-linking with antigen", <i>Clin. Exp. Immunol.</i> 98:229-233.
	BM	Basombrio (1970) "Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene", <i>The Institute for Cancer Research</i> 30:2458-2462.
	BN	Bensaude et al. (1983) "Spontaneous high expression of heat-shock proteins in mouse embryonal carcinoma cells and ectoderm from day 8 mouse embryo", <i>EMBO J.</i> 2:173-177.
	BO	Blachere et al. (1993) "Heat Shock Protein Vaccines Against Cancer," <i>Journal of Immunotherapy</i> 14:352-356.
	BP	Blachere and Srivastava (1993) "Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells", <i>J. Cellular Biochem. Keystone Symposia</i> NZ502, p. 124.
	BQ	Boon (1992) "Toward a genetic analysis of tumor rejection antigens", <i>Advances in Cancer Research</i> 58:177-210.
	BR	Cohen (1993) "Cancer Vaccines Get A Shot In the Arm", <i>Science</i> 262:841-843.
	BS	Craig (1993) "Chaperones: Helpers Along the Pathways to Protein Folding", <i>Science</i> 260:1902-1904.
	BT	Ebert (1987) "Characterization of an immunosuppressive factor derived from colon cancer cells", <i>J. Immunol.</i> , 138(7):2161-2168.
	BU	Elliott et al. (1990) "Naturally Processed Peptides", <i>Nature</i> 348:195-197.
	BV	Falk et al. (1991) "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC Molecules", <i>Nature</i> 351:290-296.
	BW	Falk et al. (1990) "Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules", <i>Nature</i> 348:248-251.
	BX	Fedweg and Srivastava (1993) "Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor rejection antigen", <i>Mount Sinai School of Medicine</i> NZ 206, p. 108.
	BY	Flynn et al. (1989) "Peptide binding and release by proteins implicated as catalysts of protein assembly", <i>Science</i> 245:385-390.
	BZ	Flynn et al. (1991) "Peptide-binding Specificity of the Molecular Chaperone BiP", <i>Nature</i> 353:726-730.
	CA	Franklin (1993) "Making vaccines fit the cancer", <i>New Scientist</i> 140:17.
	CB	Gething et al. (1992) "Protein Folding in the Cell", <i>Nature</i> 355:33-45.

	CC	Globerson and Feldman (1964) "Antigenic specificity of benzo[a]pyrene-induced sarcomas", <i>Journal of the National Cancer Institute</i> 32(6):1229-1242.
	CD	Heike et al. (1994) "Protective cellular immunity against a spontaneous mammary carcinoma from ras transgenic mice," <i>Immunobiology</i> 190(4-5):411-423.
	CE	Huber et al. (1982) "Protease inhibitors interfere with the transforming growth factor- β -dependent but not the transforming growth factor- β -independent pathway of tumor cell-mediated immunosuppression", <i>J. Immunol.</i> 148(1):277-284.
	CF	Jakob et al. (1993) "Small Heat Shock Proteins Are Molecular Chaperones", <i>J. Biol. Chem.</i> 268:1517-1520.
	CG	Jardetzky et al. (1991) "Identification of Self Peptides Bound to Purified HLA-B27", <i>Nature</i> 353:326-329.
	CH	Lakey et al (1987) "Identification of a peptide binding protein that plays a role in antigen presentation", <i>Proc. Natl. Acad. Sci. USA</i> 84:1659-1663.
	CI	Lanzavecchia (1993) "Identifying Strategies for Immune Intervention", <i>Science</i> 260:937-944.
	CJ	Levinson et al. (1979) "Metal Binding Drugs Induce Synthesis of Four Proteins in Normal Cells", <i>Biol Trace Element Research</i> 1:15-23.
	CK	Lévy (1991) "ATP is Required for In Vitro Assembly of MHC Class I Antigens but Not for Transfer of Peptides across the ER Membrane", <i>Cell</i> 67:265-274.
	CL	Li et al. (1994) "A critical contemplation on the role of heat shock proteins in transfer of antigenic peptides during antigen presentation", <i>Behring Institute Mitteliungen</i> 94:37-47.
	CM	Li and Srivastava (1993) "Tumor rejection antigen gp96/grp94 is an ATPase: Implications for protein folding and antigen presentation", <i>EMBO J.</i> 12(8):3143-3151.
	CN	Lindquist and Craig (1988) "The heat-shock proteins", <i>Ann. Rev. Genet.</i> 22:631-677.
	CO	Luescher et al. (1991) "Specific Binding of Antigenic Peptides to Cell-associated MHC Class I Molecules", <i>Nature</i> 351:72-77.
	CP	Lukacs et al. (1993) "Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors", <i>J. Exp. Med.</i> 178:343-348.
	CQ	Lussow et al. (1991) "Mycobacterial heat-shock proteins as carrier molecules", <i>Eur. J. Immunol.</i> 21:2297-2302.
	CR	Madden et al. (1991) "The Structure of HLA-B27 Reveals Nonamer Self-peptides Bound in an Extended Conformation", <i>Nature</i> 353:321-325.
	CS	Maki et al. (1993) "Mapping of the Genes for Human Endoplasmic Reticular Heat Shock Protein gp96/grp94", <i>Somatic Cell Mol. Genetics</i> 19(1):73-81.
	CT	Maki et al. (1990) "Human homologue of murine tumor rejection antigen gp96: 5'-Regulatory and coding regions and relationship to stress-induced proteins", <i>Proc. Natl. Acad. Sci. USA</i> 87:5658-5663.
	CU	McCall et al. (1989) "Biotherapy: A New Dimension in Cancer Treatment", <i>Biotechnology</i> 7:231-240.
	CV	Melnick (1985) "Virus Vaccines: An Overview", <i>Proceedings of the First Annual Southwest Foundation for Biomedical Research International Symposium, Houston, Texas, 8-10 November 1984, American Society for Microbiology</i> pp. 1-13.
	CW	Mizoguchi et al. (1982) "Alternation in signal transduction molecules in T lymphocytes from tumor-bearing mice", <i>Science</i> 258:1795-1798.
	CX	Nelson et al. (1992) "The Translation Machinery and 70 kd Heat Shock Protein Cooperate in Protein Synthesis", <i>Cell</i> 71:97-105.
	CY	Palladino et al. (1987) "Expression of shared tumor-specific antigen by two chemically induced BALB/c sarcomas", <i>Cancer Research</i> 47:5074-5079.
	CZ	Prehn and Main (1957) "Immunity to methylcholanthrene-induced sarcomas", <i>Journal of the National Cancer Institute</i> 18(6):769-778.
	DA	Rothman (1989) "Polypeptide Chain Binding Proteins: Catalysts of Protein Folding and Related Processes in Cells", <i>Cell</i> 59:591-601.
	DB	Rötzschke et al. (1990) "Isolation and Analysis of Naturally Processed Viral Peptides as Recognized by Cytotoxic T cells", <i>Nature</i> 348:248-251.
	DC	Salk et al. (1993) "A Strategy for Prophylactic Vaccination Against HIV", <i>Science</i> 260:1270-1272.

DD	Schumacher et al. (1991) "Peptide Selection by MHC Class I Molecules", <i>Nature</i> 350:703-706.
DE	Srivastava et al. (1991) "Protein Tumor Antigens", <i>Curr. Opin. Immunol.</i> 3:654-658.
DF	Srivastava et al. (March 1993) "Evidence for peptide-chaperoning by the endoplasmic reticular heat shock protein GP96: Implications for vaccination against cancer and infectious diseases", <i>J Cell Biochem Suppl</i> 17D:94 (Abstract NZ014).
DG	Srivastava et al. (1984) "The Serologically Unique Cell Surface Antigen of Zajdela Ascitic Hepatoma is also its Tumor-Associated Transplantation Antigen", <i>Int. J. Cancer</i> 33:417-422.
DH	Srivastava et al. (1989) "Identification of a Human Homologue of the Murine Tumor Rejection Antigen GP96," <i>Cancer Res.</i> 49:1341-1343.
DI	Srivastava et al. (1988) "Individually Distinct Transplantation Antigens of Chemically Induced Mouse", <i>Immunology Today</i> 9:78-83.
DJ	Srivastava et al. (1987) "5'-Structural analysis of genes encoding polymorphic antigens of chemically induced tumors", <i>Proc. Natl. Acad. Sci. USA</i> 84:3807-3811.
DK	Srivastava et al. (1993) "Peptide-Binding Heat Shock Proteins in the Endoplasmic Reticulum: Role in Immune Response to Cancer and in Antigen Presentation", <i>Advances in Cancer Research</i> 62:153-177.
DL	Srivastava and Maki (1991) "Stress-induced proteins in immune response cancer", <i>Microbiol. Immunol.</i> 167:109-123.
DM	Srivastava and Heike (1986) "Tumor-specific immunogenicity of stress-induced proteins: Convergence of two evolutionary pathways of antigen presentation?", <i>Seminars in Immunology</i> 3:57-64.
DN	Srivastava et al. (1986) "Tumor rejection antigens of chemically induced sarcomas of inbred mice", <i>Proc. Natl. Acad. Sci. USA</i> 83:3407-3411.
DO	Srivastava (1991) "Tumor-specific Immunogenicity of Stress-induced Proteins: Covergence of Two Evolutionary Pathways of Antigen Presentation?", <i>Semin Immunol.</i> 1991 Jan;3(1):57-64.
DP	Srivastava et al. (1994) "Heat Shock Proteins Transfer Peptides During Antigen Processing and CTL Priming", <i>Immunogenetics</i> 39:93-98.
DQ	Subbarao et al. (1992) "A General Overview of Viral Vaccine Development," <i>Genetically Engineered Vaccines</i> 327:51-57.
DR	Szikora et al. (1990) "Structure of the gene of tum-transplantation antigen P35B presence of a point mutation in the antigenic allele", <i>EMBO J.</i> 9(4):1041-1050.
DS	Thomas et al. (1982) "Molecular and Cellular Effects of Heat Shock and Related Treatments of Mammalian Tissue-Culture Cells", <i>Cold Spring Harbor Symp Quant Biol</i> 46:985-996.
DT	Udono (1993) "Heat shock proteins HSP70, HSP90 and GP96 elicit tumor specific immunity to the tumors from which they are isolated", <i>J. Cell. Biochem. Suppl.</i> 17D:113 (Abstract NZ225).
DU	Udono et al. (1993) "Heat Shock Protein 70-associated Peptides Elicit Specific Cancer Immunity", <i>J. Exp. Med.</i> 178:1391-1396.
DV	Udono et al. (1994) "Comparison of Tumor-Specific Immunogenicities of Stress-Induced Proteins gp96, hsp90, and hsp70", <i>J. Immunol.</i> 152:5398-5403.
DW	Udono et al. (1994) "Cellular requirements for tumor-specific immunity elicited by heat shock proteins: Tumor rejection antigen gp96 primes CD8+ T cells in vivo", <i>Proc. Natl. Acad. Sci. (USA)</i> 91:3077-3081.
DX	Ullrich et al. (1986) "A mouse tumor-specific transplantation antigen is a heat shock-related protein", <i>Proc. Natl. Acad. Sci. USA</i> 83:3121-3125.
DY	Vanbuskirk et al. (1989) "Peptide binding protein having a role in antigen presentation is a member of the hsp70 heat shock family", <i>J. Exp. Med.</i> 170:1799-1809.
DZ	Van den Enyde et al. (1991) "The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice", <i>J. Exp. Med.</i> 173:1373-1384.
EA	Vitanen et al. (1992) "Mammalian Mitochondrial Chaperonin 60 Functions as a single Toroidal Ring", <i>J. Biol. Chem.</i> 267:695-698.
EB	Welch et al. (1982) "Purification of the Major Mammalian Heat Shock Proteins", <i>J. Biol. Chem.</i> 257:14949-14959.
EC	Welch et al. (1985) "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the Proteins for Nucleotides", <i>Mol. Cell. Biol.</i> 5:1229-1237.

	ED	Welch (1993) "How Cells Respond to Stress", <i>Scientific American</i> pp. 56-64.
	EE	Young (1990) "Stress Proteins and Immunology", <i>Annu. Rev. Immunol.</i> 8:401-420.
	EF	Yu et al. (1991) "Sequence Analysis of Peptides Bound to MHC Class II Molecules", <i>Nature</i> 353:622-627.
	EJ	Maki (1991) "The Human Homologue of the Mouse Tumor Rejection Antigen GP96", Ph.D. thesis, Cornell University.
	EK	Srivastava and Old (1989) "Gp96 Molecules: Recognition Elements in Tumor Immunity", <i>Human Tumor Antigens and Specific Tumor Therapy</i> , pages 63-71.
	EL	Srivastava et al. (1990) "Immunization with Soluble Gp96 Antigens Elicits Tumor-Specific Cellular Immunity", <i>Cellular Immunity and the Immunotherapy of Cancer</i> , pages 307-314

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.